A Marie Skłodowska-Curie Innovative Training Network (ITN)

Real-time Adaptive Particle Therapy of Cancer (RAPTOR)

RAPTOR brings together 13 Beneficiaries and 15 partner organizations with one aim in common: To bring adaptive particle therapy to the clinic.

Beneficiaries & partners

Funded by the Horizon 2020 Framework Programme of the EU.

Introduction

The high precision of PT comes as a double-edged sword since PT is normally less robust than X-ray radiotherapy. Several uncertainties, such as changes in anatomy, positioning, organ delineation and systematic uncertainties can have a significant impact on where the final dose is delivered. The reliability of PT has increased in recent years with robust treatment planning, however, it still remains sensitive to larger uncertainties that have to be minimized to exploit the full benefit of PT.

The clinical workflow in PT has been adopted from conventional X-ray radiotherapy, where the treatment plan is based on the initial computed tomography (CT) scan of a patient. Since, the treatment usually lasts several weeks, it is likely that the initial treatment plan becomes less valid due to the changes of the patient anatomy as the treatment progresses.

We propose a shift in the paradigm

RAPTOR CONSORTIUM

Towards Interventional Particle Therapy for Advanced Cancer Care

Actual information & project findings

News & Articles

Articles

RAPTOR White Paper

Towards Interventional Particle Therapy for Advanced Cancer Care Introduction Particle therapy (PT) has advantageous physical properties for radiotherapy when compared to conventional X-rays. Instead of

Read More »

Member of RAPTOR Consortium

RAPTOR brings together 13 Beneficiaries and 15 partner organizations from all over Europe with one aim in common: To bring adaptive particle therapy to the clinic.

Don't hesitate to contact us

Send Us A Message